{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-QXEWNNVC/4044122a-8dd5-4dbb-8b8a-102f9a21d795/HTML","dcterms:extent":"17 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-QXEWNNVC/59166630-9db1-40f6-8039-51ba0df5176f/PDF","dcterms:extent":"74 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-QXEWNNVC/b9191f1f-bbbd-4164-8132-a57d0a13c9f6/TEXT","dcterms:extent":"16 KB"}],"edm:TimeSpan":{"@rdf:about":"1929-2026","edm:begin":{"@xml:lang":"en","#text":"1929"},"edm:end":{"@xml:lang":"en","#text":"2026"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-QXEWNNVC","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp"},{"@xml:lang":"sl","#text":"Zdravniški vestnik"}],"dcterms:issued":"2003","dc:creator":["Dovšak, Tadej","Zver, Samo"],"dc:format":[{"@xml:lang":"sl","#text":"letnik:72"},{"@xml:lang":"sl","#text":"številka:9"},{"@xml:lang":"sl","#text":"str. 499-501"}],"dc:identifier":["ISSN:1318-0347","COBISSID:16995545","URN:URN:NBN:SI:doc-QXEWNNVC"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"dc:subject":[{"@xml:lang":"en","#text":"Adverse Effects"},{"@xml:lang":"en","#text":"Chemically Induced"},{"@xml:lang":"sl","#text":"citostatiki"},{"@xml:lang":"sl","#text":"Črevesna psevdoobstrukcija"},{"@xml:lang":"en","#text":"Drug Therapy"},{"@xml:lang":"sl","#text":"gastroenterologija"},{"@xml:lang":"sl","#text":"ileus"},{"@xml:lang":"en","#text":"Intestinal Pseudo-Obstruction"},{"@xml:lang":"en","#text":"Itraconazole"},{"@xml:lang":"en","#text":"Itrakonazol"},{"@xml:lang":"en","#text":"Leukemia, Lymphocytic, Acute"},{"@xml:lang":"sl","#text":"levkemija"},{"@xml:lang":"sl","#text":"Levkemija limfocitna, akutna"},{"@xml:lang":"en","#text":"Middle Age"},{"@xml:lang":"sl","#text":"Srednja leta"},{"@xml:lang":"en","#text":"therapy"},{"@xml:lang":"en","#text":"Vincristine"},{"@xml:lang":"sl","#text":"Vinkristin"},{"@xml:lang":"sl","#text":"zapleti"},{"@xml:lang":"sl","#text":"zdravljenje"}],"dcterms:temporal":{"@rdf:resource":"1929-2026"},"dc:title":{"@xml:lang":"sl","#text":"Paralitični ileus kot zaplet zdravljenja z vinkristinom in itrakonazolom| Paralytic ileus as a side effect of vincristine and itraconazole treatment|"},"dc:description":[{"@xml:lang":"sl","#text":"Background. Vincristin is an important and frequently used chemoterapeutic drug in the treatment of malignant lymphoproliferative disease. Among its sideeffects are well known bone marrow supression and polyneuropathia. But common physicians are not familiar with vincristine bowel peristaltics inhibitory effect. Patient and methods. This study presents 64 years old patient with acute lymphoblastic leukemia (ALL) who was treated with chemotherapy which included vincristine. Two weeks after the treatment startedparalytic ileus developed which was later sucessfully treated with laxatives and prokynetic drugs. Secondary causes for ileus development were excluded. Literature data was reviewed and a higher incidence of paralytic ileus in vincristine treated patients was found, especially when they are given concomitant itraconazole. Our patient received concommitant itraconazoleas a part of antifungal prophylaxis against invasive aspergillosiswhich is a perceived routine on hematological departments. Conclusions. Vincristine treated patients should be carefully observed regarding bowel peristaltics and obstipation. If obstipation or even paralyticileus developes, we must stop vincristine therapy. All patients receiving vincristine must receive fluconazol instead of itraconazol as a partof antifungal prophylaxis"},{"@xml:lang":"sl","#text":"Izhodišča. Vinkristin je nepogrešljiv citostatik pri zdravljenju malignih limfoproliferativnih bolezni. Med stranskimi učinki zdravila sta dobro poznananjegov zaviralni učinek na kostni mozeg in polinevropatija. Navadno pa lečeči zdravniki prezremo njegov zaviralni učinek na črevesno peristaltiko. Bolnik in metode. Predstavljen je 64-letni bolnik z akutno limfoblastno levkemijo (ALL), zdravljen s kombinirano kemoterapijo, ki je vključevala tudi vinkristin. Dva tedna po začetku zdravljenja je prišlo do nastanka paralitičnega ileusa, ki se je razrešil po dolgotrajnem zdravljenju z odvajaliin prokinetiki. S preiskavami smo izključili sekundarni vzrok za nastanek ileusa. Ob pregledu literature smo ugotovili, da je incidenca paralitičnega ileusa pri bolnikih, zdravljenih z vinkristinom, še posebej visoka, če hkrati prejemajo tudi itrakonazol. Tudi v našem primeru je bolnik prejemal itrakonazol, ki ga na hematoloških oddelkih pogosto uporabljamo za preprečevanje glivičnih okužb, predvsem invazivne aspergiloze. Zaključki. Pri bolnikih, ki prejemajo vinkristin, moramo biti pozorni na pojav zaprtja. Če sepojavi zaprtje ali pa pride celo do nastanka paralitičnega ileusa, potem moramo prenehati zdraviti z vinkristinom. Vsi bolniki, ki prejemajo vinkristin, naj kot protiglivično preventivno zdravljenje prejemajo flukonazolin ne itrakonazol"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-QXEWNNVC","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-QXEWNNVC"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-QXEWNNVC/59166630-9db1-40f6-8039-51ba0df5176f/PDF"},"edm:rights":{"@rdf:resource":"http://creativecommons.org/licenses/by-nc/4.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko zdravniško društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-QXEWNNVC/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-QXEWNNVC"}}}}